DE602005026724D1 - Verfahren zur verwendung von aus fettgewebe stammenden zellen bei der behandlung von herz-kreislauf-leiden - Google Patents

Verfahren zur verwendung von aus fettgewebe stammenden zellen bei der behandlung von herz-kreislauf-leiden

Info

Publication number
DE602005026724D1
DE602005026724D1 DE602005026724T DE602005026724T DE602005026724D1 DE 602005026724 D1 DE602005026724 D1 DE 602005026724D1 DE 602005026724 T DE602005026724 T DE 602005026724T DE 602005026724 T DE602005026724 T DE 602005026724T DE 602005026724 D1 DE602005026724 D1 DE 602005026724D1
Authority
DE
Germany
Prior art keywords
cells
sleeping
fat
treatment
regenerative cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005026724T
Other languages
English (en)
Inventor
John K Fraser
Marc H Hedrick
Min Zhu
Brian M Strem
Eric Daniels
Isabella Wulur
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cytori Therapeutics Inc
Original Assignee
Cytori Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37452485&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE602005026724(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cytori Therapeutics Inc filed Critical Cytori Therapeutics Inc
Publication of DE602005026724D1 publication Critical patent/DE602005026724D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/35—Fat tissue; Adipocytes; Stromal cells; Connective tissues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1891—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0653—Adipocytes; Adipose tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Developmental Biology & Embryology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Dispersion Chemistry (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE602005026724T 2005-05-25 2005-05-25 Verfahren zur verwendung von aus fettgewebe stammenden zellen bei der behandlung von herz-kreislauf-leiden Active DE602005026724D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2005/018605 WO2006127007A2 (en) 2005-05-25 2005-05-25 Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions

Publications (1)

Publication Number Publication Date
DE602005026724D1 true DE602005026724D1 (de) 2011-04-14

Family

ID=37452485

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005026724T Active DE602005026724D1 (de) 2005-05-25 2005-05-25 Verfahren zur verwendung von aus fettgewebe stammenden zellen bei der behandlung von herz-kreislauf-leiden

Country Status (12)

Country Link
EP (2) EP2465923B1 (de)
JP (1) JP5210155B2 (de)
KR (2) KR101278437B1 (de)
CN (1) CN101443023A (de)
AT (1) ATE500319T1 (de)
AU (1) AU2005332046B2 (de)
CA (1) CA2609361C (de)
DE (1) DE602005026724D1 (de)
DK (1) DK1885382T3 (de)
ES (1) ES2364689T3 (de)
PL (1) PL1885382T3 (de)
WO (1) WO2006127007A2 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002357135C1 (en) 2001-12-07 2009-01-22 Macropore Biosurgery, Inc. Systems and methods for treating patients with processed lipoaspirate cells
US9597395B2 (en) 2001-12-07 2017-03-21 Cytori Therapeutics, Inc. Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions
US7771716B2 (en) 2001-12-07 2010-08-10 Cytori Therapeutics, Inc. Methods of using regenerative cells in the treatment of musculoskeletal disorders
US20050095228A1 (en) 2001-12-07 2005-05-05 Fraser John K. Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders
US20050048035A1 (en) 2001-12-07 2005-03-03 Fraser John K. Methods of using regenerative cells in the treatment of stroke and related diseases and disorders
US8062286B2 (en) 2005-03-23 2011-11-22 Shippert Ronald D Tissue transplantation method and apparatus
US7780649B2 (en) 2005-03-23 2010-08-24 Shippert Ronald D Tissue transplantation method and apparatus
US7794449B2 (en) 2005-03-23 2010-09-14 Shippert Ronald D Tissue transplantation method and apparatus
US8622997B2 (en) 2005-03-23 2014-01-07 Ronald D. Shippert Tissue transfer method and apparatus
US7789872B2 (en) 2005-03-23 2010-09-07 Shippert Ronald D Tissue transplantation method and apparatus
US9581942B1 (en) 2005-03-23 2017-02-28 Shippert Enterprises, Llc Tissue transfer method and apparatus
ES2325715B1 (es) 2007-08-03 2010-06-17 Genetrix, S.L. Poblacion de celulas madre adultas derivadas de tejido adiposo cardiaco y su uso en regeneracion cardiaca.
WO2010021993A1 (en) 2008-08-19 2010-02-25 Cytori Therapeutics, Inc. Methods of using adipose tissue-derived cells in the treatment of the lymphatic system and malignant disease
KR101679671B1 (ko) * 2009-10-27 2016-11-28 도병록 재생성 세포 추출 시스템
US8887770B1 (en) 2011-03-17 2014-11-18 Ronald D. Shippert Vessel fill control method and apparatus
CN102151153A (zh) * 2011-03-25 2011-08-17 吴成翰 外科手术过程中组织碎片的回收装置
JP5628131B2 (ja) * 2011-10-19 2014-11-19 サイトリ セラピューティクス インコーポレイテッド 心血管状態の治療において脂肪組織由来細胞を使用する方法
EP2677024B1 (de) * 2012-06-22 2019-11-20 Human Med AG Vorrichtung zum Separieren von adulten Stammzellen
US9259435B2 (en) * 2012-08-31 2016-02-16 W. L. Gore & Associates, Inc. Reactive oxidative species generating materials and methods of use
US9468709B2 (en) 2012-11-12 2016-10-18 Shippert Enterprises, Llc Syringe fill method and apparatus
US9580678B2 (en) 2013-06-21 2017-02-28 The Regents Of The University Of California Microfluidic tumor tissue dissociation device
JP6427202B2 (ja) * 2014-02-28 2018-11-21 ビーディービーシー サイエンシーズ コーポレイション 組織操作のためのシステム
US10772997B2 (en) 2014-05-15 2020-09-15 Ronald D. Shippert Tissue parcelization method and apparatus
DE102015109148B3 (de) * 2015-06-10 2016-05-04 Human Med Ag Vorrichtung zum Separieren von regenerativen und adulten Stammzellen
CN106318905A (zh) * 2015-07-10 2017-01-11 中国科学院上海生命科学研究院 血栓烷素a2受体作为脂肪干细胞治疗缺血性疾病的靶标
SG11201806177QA (en) * 2016-01-19 2018-08-30 Univ Osaka Transplant material for treatment of heart disease
US10722540B1 (en) 2016-02-01 2020-07-28 The Regents Of The University Of California Microfluidic device and method for shear stress-induced transformation of cells
KR102579835B1 (ko) 2016-06-08 2023-09-15 더 리전트 오브 더 유니버시티 오브 캘리포니아 조직 및 세포를 프로세싱하기 위한 방법 및 장치
JP6256786B1 (ja) * 2017-04-12 2018-01-10 学校法人福岡大学 不妊症の処置に用いられる医薬組成物およびその製造方法
CN107988151A (zh) * 2017-12-06 2018-05-04 北京大学第三医院 一种体外诱导带血管蒂的脂肪组织成肌方法
WO2021158045A1 (ko) * 2020-02-04 2021-08-12 주식회사 히에라바이오 줄기세포를 포함하는 심막 내 주입용 조성물 및 이의 용도

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US482820A (en) 1892-09-20 Ernest p
US6238908B1 (en) 1995-06-07 2001-05-29 Aastrom Biosciences, Inc. Apparatus and method for maintaining and growth biological cells
FR2742662B1 (fr) 1995-12-21 1998-01-23 Centre Nat Rech Scient Anticorps anti-idiotypiques du facteur de croissance endotheliale vasculaire et leur utilisation comme medicaments
US5919234A (en) 1996-08-19 1999-07-06 Macropore, Inc. Resorbable, macro-porous, non-collapsing and flexible membrane barrier for skeletal repair and regeneration
US6280473B1 (en) 1996-08-19 2001-08-28 Macropore, Inc. Resorbable, macro-porous, non-collapsing and flexible membrane barrier for skeletal repair and regeneration
CA2296704C (en) * 1997-07-14 2010-10-19 Osiris Therapeutics, Inc. Cardiac muscle regeneration using mesenchymal stem cells
US6269716B1 (en) 1998-11-18 2001-08-07 Macropore, Inc. High-torque resorbable screws
CA2327789C (en) 1998-04-07 2007-09-04 Macropore, Inc. Membrane with tissue-guiding surface corrugations
US6001642A (en) 1998-06-29 1999-12-14 Wyle Laboratories, Inc. Life Sciences Bioreactor and cell culturing processes using the bioreactor
US6653146B1 (en) 1999-11-15 2003-11-25 Chemclean Corporation Bio-burden visualization system
PT1852087E (pt) 2000-03-10 2011-07-25 Mast Biosurgery Ag Micromembrana reabsorvível para atenuação de tecido cicatricial
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
WO2002028472A2 (en) 2000-10-04 2002-04-11 James Peter Amis Non-scatterable, radio-opaque marker for medical imaging applications
FR2819265B1 (fr) * 2001-01-10 2004-01-02 Centre Nat Rech Scient Cellules du tissu adipeux extramedullaire et leurs applications dans la reconstitution des lignees hematopoietiques
JP2004532202A (ja) * 2001-03-15 2004-10-21 シアオ，ヨング−フー 生存哺乳動物における臨床的に認められた形態の心臓の病状を治療的に処置する方法
US20050008626A1 (en) * 2001-12-07 2005-01-13 Fraser John K. Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions
AU2002357135C1 (en) * 2001-12-07 2009-01-22 Macropore Biosurgery, Inc. Systems and methods for treating patients with processed lipoaspirate cells
JP2004099471A (ja) * 2002-09-05 2004-04-02 Cardio Corp 心筋梗塞および心不全の治療薬
WO2004074457A2 (en) * 2003-02-20 2004-09-02 Macropore Biosurgery, Inc. Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions
CN1842589B (zh) * 2003-06-25 2012-04-25 马克罗珀尔生物外科公司 用于从组织分离并且浓缩再生细胞的***和方法
JP5019511B2 (ja) * 2003-09-17 2012-09-05 サイトリ セラピューティクス インコーポレイテッド 抹消血管疾患およびそれに関連する障害の治療において新生細胞を利用する方法
JP4336821B2 (ja) * 2003-12-25 2009-09-30 有限会社金沢大学ティ・エル・オー 哺乳動物の骨髄細胞または臍帯血由来細胞と脂肪組織を利用した心筋細胞の誘導

Also Published As

Publication number Publication date
PL1885382T3 (pl) 2011-09-30
EP2465923A3 (de) 2012-06-27
KR101400544B1 (ko) 2014-05-27
JP2008545687A (ja) 2008-12-18
ES2364689T3 (es) 2011-09-12
CA2609361C (en) 2017-11-14
KR20080017389A (ko) 2008-02-26
CA2609361A1 (en) 2006-11-30
CN101443023A (zh) 2009-05-27
EP1885382A4 (de) 2009-09-09
KR20130038412A (ko) 2013-04-17
WO2006127007A3 (en) 2009-04-16
EP1885382B1 (de) 2011-03-02
EP2465923B1 (de) 2018-04-11
WO2006127007A2 (en) 2006-11-30
AU2005332046A1 (en) 2006-11-30
DK1885382T3 (da) 2011-06-20
EP1885382A2 (de) 2008-02-13
JP5210155B2 (ja) 2013-06-12
KR101278437B1 (ko) 2013-06-25
EP2465923A2 (de) 2012-06-20
AU2005332046B2 (en) 2013-05-16
ATE500319T1 (de) 2011-03-15

Similar Documents

Publication Publication Date Title
DE602005026724D1 (de) Verfahren zur verwendung von aus fettgewebe stammenden zellen bei der behandlung von herz-kreislauf-leiden
ATE524070T1 (de) Verfahren zur verwendung von aus fettgewebe stammenden zellen bei der behandlung von herz- kreislauf-leiden
SG146666A1 (en) Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders
WO2006014159A3 (en) Methods of using regenerative cells in the treatment of musculoskeletal disorders
DE602006007093D1 (de) Kombinationstherapie zur Behandlung von Diabetes und dadurch bedingten Leiden sowie zur Behandlung von mittels Erhöhung des GLP-1-Spiegels im Blut verbesserten Leiden
ATE501247T1 (de) Verfahren zur verwendung regenerativer zellen zur förderung der wundheilung
ATE355852T1 (de) Verwendung von botulinum toxin zur behandlung von herz- und kreislaufskrankheiten
DE602006017071D1 (de) Zusammensetzungen und verfahren zur behandlung von herzkrankheiten
DE602005026866D1 (de) Vewendung von dreidimensionalem kultiviertem gewebe zur behandlung von kongestivem herzversagen
BR112018072714A2 (pt) composições de ligação a hcl para e método de tratamento de distúrbios de ácido-base
MX2021013880A (es) Polimeros enlazados al proton para administracion oral.
WO2006022612A3 (en) Methods of using regenerative cells in the treatment of stroke and related diseases and disorders
EA201591522A1 (ru) Лечение реакции трансплантат против хозяина у подвергаемых трансплантации пациентов
ATE478942T1 (de) Verfahren zur verwendung regenerativer zellen bei der behandlung von nierenkrankheiten und störungen
DE602005024148D1 (de) Verwendung der kombination aus temozolomid und tnf-alpha zur behandlung von glioblastoma
ATE487480T1 (de) Perhexilin zur behandlung von chronischer herzinsuffizienz
DE602004030661D1 (de) Verwendung von kahalalide verbindungen zur herstellung eines arzneimittels zur behandlung von psoriasis
TW201614066A (en) Composition for treatment of joint disease and method thereof
DE602004016547D1 (de) 1,4-dihydropyridinverbindungen, pharmazeutische verbindungen, und verfahren zur behandlung von herzkreislauferkrankungen
MX2011011114A (es) Materiales y metodos para utilizar celulas madre de tejido adiposo para tratar una lesion y enfermedad pulmonar.
ATE526984T1 (de) Knochen-morphogenetische proteine zur verwendung zur behandlung und prävention von neuroblastomen
EA201600229A1 (ru) Бис(5-амино-1,4-диоксо-1,2,3,4-тетрагидрофталазин-2-ил)цинк, способ его получения, фармацевтическая композиция на его основе, лечебные средства на его основе, способ лечения кожных заболеваний и способ лечения гастрита
DE602004015321D1 (de) 1,4-dihydropyridinverbindungen, pharmazeutische verbindungen, und verfahren zur behandlung von herzkreislauferkrankungen
ATE511396T1 (de) Therapeutische zusammensetzungen enthaltend thromboserin oder dessen salze zur verwendung in der prophylaxe oder behandlung von thrombose in patienten mit blutungsrisiko
WO2004024041A1 (ja) 温熱治療方法